RESEARCH
 

Research in the Wittrup group is predominantly focused on the application of protein engineering to the development of cancer therapeutics.

Tumor targeting
(NCI CA101830, NCI CCNE)

Development of optimized proteins and protocols for selectively delivering radiometals and toxins to tumor cells.

Lab Researchers: Michael Schmidt, Greg Thurber, Margaret E. Pawlowski, Kelly Davis, Chris Pirie

Collaborators:  John Frangioni, BIDMC, Sangeeta Bhatia, MIT, Jack Wands, Brown University, Michael Rosenblum, MD Anderson Cancer Center, Steve Larson, MSKCC.

Engineered Antibody EGFR Antagonist Cancer Therapeutics (NCI CA96504)

Structure/function & trafficking studies of antibody antagonism of the epidermal growth factor receptor, involved in many cancers.

Lab Researchers: Jamie Spangler, Steve Sazinsky, Ben Hackel

Collaborators: Doug Lauffenburger, MIT, Bruce Tidor, MIT, and John Kuriyan, UC Berkeley.

Tumor Immunotherapy
(NIAID AI065824)
Presentation of tumor antigens to the immune system together with stimulatory signals that mimic a pathogenic infection to attempt to raise a protective immune response. Engineering altered binding properties of interleukin 2 to enhance T cell signaling properties. 

Lab Researchers: Shanshan Wu Howland, Eileen Higham, Jordi Mata-Fink, Annie Gai, David Liu

Collaborators: David Hafler, Harvard, Jianzhu Chen, MIT, Doug Lauffenburger, MIT, Forest White, MIT, and Garry Nolan, Stanford.

top